Introduction
============

Psoriatic arthritis (PsA) is a chronic inflammatory arthritis characterized by both peripheral articular manifestations and axial skeletal involvement \[[@ref1]-[@ref3]\]. It affects approximately 2% to 3% of the population globally, with the majority of patients experiencing a chronic, progressive course of disease developing to a destructive, disabling form of arthritis over time \[[@ref1]\]. Conventional therapies for psoriasis have not been fully satisfactory and natural products (NPs)---anecdotally known to be highly effective (though with little formal scientific research evidence)---represent important treatment options for psoriasis \[[@ref4]-[@ref8]\]. PsA is considered a systemic inflammatory disease with multifactorial (environmental and genetic) factors contributing to its pathogenesis. Accordingly, a lead compound which simultaneously effects different targets would be ideal for the improved treatment of PsA \[[@ref4],[@ref9]\]. The practice of combining NPs into formulations, a common method in Chinese medicine, could prove to be an effective alternative approach for the development of multi-compound, multi-target therapies \[[@ref10]\].

For PsA, joint damage results from the release of the direct bone-resorbing factors osteoclasts (OCs) and metalloproteinases. An increased frequency of osteoclast precursor (OCP) is found in most patients with PsA and correlates with the extent of radiographic damage observed in affected patients. In osteoclastogenesis, peripheral OCPs and cluster of differentiation (CD) 14^+^ monocytes differentiate to OCs \[[@ref11]\]. Disordered osteoclastogenesis leads to altered bone remodeling causing bone erosion and joint damage, represented by increased osteoclast precursors numbers, radiographic damage scores, and disease activity index \[[@ref3],[@ref12]\]. Typically, this correlates with increased serum levels of the following cellular biomarkers: (1) macrophage-colony stimulating factor (M-CSF); (2) tumor necrosis factor alpha (TNF-α); (3) osteoprotegerin (OPG); (4) receptor activator of nuclear factor-κB ligand (RANKL); (5) CD14^+^/CD11b^+^/CD16^+^; and (7) interleukin (IL-23/IL-17) \[[@ref3],[@ref11],[@ref12]\]. Accordingly, our research direction will focus on the impact of NPs on the above biomarkers, osteoclastogenesis, and joint damage/erosion associated with PsA.

There exists an intrinsic connection between psoriasis and PsA. PsA, either on joint damage or on bone erosion, may respond to anti-psoriatic pharmacotherapy (APP), APP-like NPs, and their natural compounds. A psoriasis study recently developed a novel approach for the identification of promising NPs for psoriasis therapy based on an extensive literature review of current clinical evidence available, followed by an in silico screening of biological targets for APP and drug development. This approach extends beyond psoriasis and can be applied to similar diseases with multifactorial causes for which multi-compound, multi-target therapies are emerging as the therapeutic norm. This approach has been successfully applied in psoriasis and generated robust preliminary data identifying potential NP targets and pathways \[[@ref13]-[@ref17]\]. We have also previously undertaken in vitro and in vivo studies screening for natural compounds that affect osteoclast differentiation and osteoclast-mediated osteolysis, and identified NPs which may have therapeutic potential for the treatment of bone lytic disorders \[[@ref18]-[@ref22]\].

With this project, we aim to (1) identify specific lead natural compounds with therapeutic effects on PsA and/or other autoimmune joint disorders with a multi-target in silico, in vitro, and in vivo approach; (2) provide an overview of the relevant signaling pathways and mechanisms of action; and (3) present therapeutic targets and preclinical efficacy evaluation of APP-like NPs and their natural compounds.

Methods
=======

Preliminary Data
----------------

Previous work included the development of a novel approach to identify promising NPs for psoriasis treatment based on available clinical evidence followed by in silico screening for biological targets for APP and drug development. Using this combined approach, 9 APP-like NPs have been identified as promising candidates for psoriasis therapy ([Table 1](#table1){ref-type="table"}) \[[@ref13]-[@ref17]\].

###### 

Promising natural products for psoriasis (N=12) including 9 anti-psoriatic pharmacotherapy-like natural products.

  Scientific name                Study design                Administration   APP^a^-like NPs^b^
  ------------------------------ --------------------------- ---------------- --------------------
  *Sophora flavescens*           NPM^c^ and APP vs APP       External         Yes
  *Cnidium monnieri*             NPM and APP vs APP          External         No
  *Dictamnus dasycarpus*         NPM and APP vs APP          External         No
  *Borneolum syntheticum*        NPM and APP vs APP          External         No
  *Aloe vera*                    Single NP vs APP/placebo    External         Yes
  *Indigo naturalis*             Single NP vs APP/placebo    External         Yes
  *Camptotheca acuminata*        Single NP vs APP/placebo    External         Yes
  *Mahonia aquifolium*           Single NP vs APP/placebo    External         Yes
  *Sophora flavescens*           NP formula vs APP/placebo   External         Yes
  *Lithospermum erythrorhizon*   NP formula vs APP/placebo   External         Yes
  *Oldenlandia diffusa*          NP formula vs APP/placebo   Internal         Yes
  *Rehmannia glutinosa*          NP formula vs APP/placebo   Internal         Yes
  *Salvia miltiorrhiza*          NP formula vs APP/placebo   Internal         Yes

^a^APP: anti-psoriatic pharmacotherapy.

^b^NP: natural product.

^c^NPM: natural product medication.

The effect of the above NPs on bone erosion and arthritis are still unknown. We hypothesize that these NPs will have therapeutic effects on arthritis via the modulation of osteoclastic bone resorption and signaling pathways. Therefore, the aims of the study consist of the following 4 specific parts: (1) in silico compound identification; (2) in vitro sample preparation; (3) in vitro mechanism investigation; and (4) in vivo preclinical efficacy evaluation ([Figure 1](#figure1){ref-type="fig"}).

In Silico Identification of Prospective Natural Compounds
---------------------------------------------------------

The preliminary data will return a shortlist of promising NPs for an in silico molecular investigation on PsA. In addition to the Encyclopedia of Traditional Chinese Medicine (Encyclopedia of TCM), the Herbal Ingredients\' Targets database (HIT, China), DrugBank (Canada), and Protein ANnotation THrough Evolutionary Relationship (PANTHER, USA) will be applied in the in silico identification procedure ([Figure 2](#figure2){ref-type="fig"}). All are available in English \[[@ref13]\].

The Encyclopedia of TCM can successively locate the relevant Latin names and the contained chemical compounds with the individual and unique plant code of each promising NP species. Subsequently, HIT can access the relevant biological targets with their individual name identification (ID) and types in an Excel spreadsheet. With a dedicated search term(s) (eg, psoriatic arthritis), DrugBank can induce the reference targets (together with the previous cellular biomarkers) to be further filtered by the above biological targets.

For each identified natural compound, their known protein targets will be entered into the keyword search using the "homo sapiens" setting. For each target, the identified Gene ID will be saved a Notepad (txt) file. One Notepad file is created for each species. This file contains all the Gene IDs for all the known therapeutic targets of all the compounds that are known to be active in the species. Each file will be sequentially uploaded into the Gene List Analysis field in PANTHER. This will report the following 5 aspects in Excel for the particular species: (1) molecular function(s), (2) biological processes, (3) cellular component(s), (4) protein class, and (5) pathway(s). The Excel files will be sorted to identify the most commonly identified pathway for each species. For each of the most commonly identified pathways, all the identified proteins, excluding upstream and downstream proteins, will be entered into Excel. Since the nomenclatures used by PANTHER and by HIT differ, cross-referencing will be undertaken regarding the short and long names used for the proteins in both databases.

![Flowchart of study progression. NI: non-intervention, NP: natural product, PsA: psoriatic arthritis, CIA: collagen-induced arthritis, TCM: traditional Chinese medicine.](resprot_v6i7e132_fig1){#figure1}

![Target-directed in silico identification.](resprot_v6i7e132_fig2){#figure2}

In Vitro Sample Preparation Using the Identified Compound Sources for Drug Development
--------------------------------------------------------------------------------------

This stage includes the extraction, fractionation, isolation, purification, and the formation of a series of bioassays for the identified compounds. The extraction method is specific to the nature of the source material and target compound. It typically involves a process of drying, grinding, homogenization, or maceration of the plant. For a pure single compound, the crude extract initially needs to be fractionated into various discrete fractions containing compounds in similar polarities or molecular sizes. NP isolation is also subject to the nature of the target compound(s) presented in the crude extract or fraction. Part sample compounds may be purchased from the market or supported by the relevant group. Qualitative chemical tests, preliminary thin-layer chromatography (TLC), and/or high performance liquid chromatography-photodiode array hyphenated technique (HPLC-PDA) can be used to obtain spectral profiles from molecular mixtures or chromatographically separated samples \[[@ref23]\]. For isolation and purification, an efficient on-line purity monitoring strategy based on on-line coupling of high-speed counter-current chromatography (HSCCC) with high performance liquid chromatography-diode array detection (HPLC-DAD) will be performed. In summary, this part of project consists of the preparation of a crude extract, preparation of a 2-phase solvent system, HSCCC separation, and HPLC-DAD purity analysis of counter-current chromatography (CCC) peak fractions \[[@ref24]\].

In Vitro Investigation of Drug Candidates
-----------------------------------------

We will perform in vitro studies on compounds prepared in stage 2 to investigate their effects on osteoclastogenesis and bone resorption ([Figure 3](#figure3){ref-type="fig"}). For osteoclast formation, 1×10^4^ bone marrow macrophage (BMM) cells per well will be isolated from the femur and tibiae of 6-week-old C57BL/6 mice and will be cultured in media containing macrophage-colony stimulating factor (M-CSF) (30 ng/mL) and RANKL (100 ng/mL). After a cell viability evaluation, further investigations will be carried out using resorption pit assays, quantitative reverse transcription polymerase chain reactions (RT-PCR), western blot analysis, luciferase reporter gene activity assays, and osteoclastogenesis assays. For statistical analysis, the student Newmane-Keuls test will be applied with mean (SD) for data expression and *P* less than .05 for statistical significance \[[@ref25]\].

![Natural compound inhibitors of the RANKL pathway.](resprot_v6i7e132_fig3){#figure3}

Preclinical Efficacy Evaluation Using Animal Models
---------------------------------------------------

The collagen-induced arthritis (CIA) model is regarded as the best-studied animal model for PsA \[[@ref26]\] and will be used in this study to determine the anti-arthritic effects of NPs (as utilized in previously published work by this laboratory) \[[@ref19],[@ref21]\].

A total of 30, 9-week old female Dark Agouti (DA) rats will be used with 10 assigned to the non-arthritic control group (C). The remaining 20 rate will be induced following the CIA protocol and will be randomly assigned to either the treatment group (A) or the placebo group (B) when PsA symptoms first appear. Groups A and B will be subject to a subcutaneous injection of the purified natural compound (1 mg/kg in 0.9% saline) or 0.9% saline control every second day from onset of symptoms (clinical score 2 or greater), until tissue collection at day 14. Natural compounds differ in their bioavailability and solubility in water. As such, the proposed dosage and/or administration of may be further adjusted if required. All rats will be raised with water, 0.9% sodium chloride (NaCl) and standard rodent food ad libitum in a 22℃ and 12h illuminated daily environment. Main outcome measures include a daily macroscopic scoring system and digital calipers to measure dorsal to plantar thickness (3 times per week) of each paw. Groups will be compared with (1) serological tests including serum albumin, alanine transaminase (ALT), aspartate transaminase (AST), and bilirubin using a clinical biochemical analyzer; (2) micro-computed tomography (micro-CT) image analysis of hind paws and femora and contact radiographs for both hind feet; and (3) histopathological assessment using tartrate-resistant acid phosphatase (TRAP) staining \[[@ref27]\] of serial 5 μm sagittal sections through the digits. The latter requires at least 2 digits randomly taken from each rat. Each digit will have distal interphalangeal (DIP), proximal interphalangeal (PIP), and metatarsophalangeal (MTP) joints intact for scoring by 2 independent observers. Analysis of variance (ANOVA) and Fishers\' protected least significant difference (PLSD) tests will be applied for statistical analyses (using StatView 4.0) with *P* values less than .05 indicating statistical significance.

Results
=======

This 4-stage study will take approximately 4 years to complete and proposes to discover the effects of natural compounds against PsA through the identification of relevant signaling pathways and preclinical efficacy evaluations using animal models ([Figure 4](#figure4){ref-type="fig"}). Currently, we are in the early stages of evaluating the in silico data and detailing the in vitro effects of compounds on osteoclastogenesis and bone resorption. The findings from this research are expected to be published when the proposed studies are fully completed.

![Study timelines. Green squares represent scheduled parts.](resprot_v6i7e132_fig4){#figure4}

Discussion
==========

Significance of Findings
------------------------

Anecdotal evidence suggests that promising NPs are able to act on specific targets regulating osteoclast function and here they constitute the compounds identified for PsA drug discovery. For each identified compound, its extracted sample will be validated in a preparation bioassay such as HPLC. This can directly prove or discount a previous PANTHER prediction by demonstrating the signaling pathways associated with joint damage and/or bone erosion. Further preclinical studies will demonstrate the anti-arthritic effects of validated natural compounds. The principal methods and findings of this project can be further applied in the search of other natural compounds effective against other arthropathies.

In Silico, Multi-Targeted Approach
----------------------------------

The in silico, multi-targeted approach is a target-directed large-scale analysis using multiple databases \[[@ref13]\]. It is able to locate biological targets for NPs and APPs. Consequently, the consolidated list of APP targets could be used to screen NPs target lists. This approach could also be used to further identify APP-like NPs by filtering out those targets irrelevant to any of the APPs. This can "fish" out a specific target across NPs and APPs. The identification of protein targets related to a specific natural compound can also reflect its therapeutic molecular mechanisms and hint at potential side effects. However, the number of estimated potential targets on the human genome is huge \[[@ref28]\]. Therefore, an in silico model is necessary for large-scale data analysis to elucidate potential protein targets associated with natural compounds (including their formulae) effective against a certain disease.

That the HIT database contains a list of NPs along with their active ingredient makes this model innovative and broadens the scope of searches, ensuring the inclusion of all potentially relevant proteins \[[@ref13]\]. An additional novelty is the "APP-like" NP identification and the NP/APP property exploration. With such a database cluster, the NP target list can be matched against potential APP drug targets to identify APP-like NPs. This may provide a direct biological and/or pharmaceutical comparison between NPs and APPs, in terms of their possible effects on specific proteins, for the same disorder.

The Reliability of In Silico Screening Data
-------------------------------------------

The in silico solution extensively uses frequency effects in target identification, which provides an objective approach to short listing targets and facilitates the reliability of the in silico data to a considerable extent. On the other hand, popular targets often reflect the hot topics previously undertaken in natural product research. Due to a number of studies and reports on natural products in chronic inflammation with PsA, some inflammatory targets may be presented in high frequency within the identified data sets. It is also noted that multiple terms of a single potential target often exist in the above main databases (HIT, DrugBank, and PANTHER) \[[@ref13]\]. The variable nomenclature in different databases may impact the reliability of data when locating a crossing target. Structure-based drug docking has emerged as a valuable tool to identify lead compounds and to facilitate drug development.

Following the in silico work, we will undertake in vitro studies and an in vivo CIA preclinical trial to individually validate the anti-arthritic effects of the identified natural compounds which have shown promise to be effective against PsA *.* During this part of the project, we will adopt standardized quality control over procedures, a high performance analysis approach, and employ established animal models to ensure the study's success and feasibility.

Conclusion
----------

The in silico rapid approach is proposed as a more general method for adding value to the results of a systematic review of NPs. More importantly, the proposed study builds on a multi-targeted approach for the identification of natural compounds for future drug discovery. This innovative approach is likely to be more precise, efficient, and compatible to identify the novel natural compounds for effective treatment of PsA.
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